Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
PharmacoEconomics
Published in: PharmacoEconomics 12/2013

01-12-2013 | Systematic Review

Cost Effectiveness of Medication Adherence-Enhancing Interventions: A Systematic Review of Trial-Based Economic Evaluations

Authors: Edwin J. M. Oberjé, Reina J. A. de Kinderen, Silvia M. A. A. Evers, Cees M. J. van Woerkum, Marijn de Bruin

Published in: PharmacoEconomics | Issue 12/2013

Login to get access

Abstract

Background

In light of the pressure to reduce unnecessary healthcare expenditure in the current economic climate, a systematic review that assesses evidence of cost effectiveness of adherence-enhancing interventions would be timely.

Objective

Our objective was to examine the cost effectiveness of adherence-enhancing interventions compared with care as usual in randomised controlled trials, and to assess the methodological quality of economic evaluations.

Methods

MEDLINE, PsycInfo, EconLit and the Centre for Reviews and Dissemination databases were searched for randomised controlled trials reporting full economic evaluations of adherence-enhancing interventions (published up to June 2013). Information was collected on study characteristics, cost effectiveness of treatment alternatives, and methodological quality.

Results

A total of 14 randomised controlled trials were included. The quality of economic evaluations and the risk of bias varied considerably between trials. Four studies showed incremental cost-effectiveness ratios (ICERs) below the willingness-to-pay threshold. Few studies seemed to evaluate interventions that successfully changed adherence.

Conclusions

Only 14 randomised controlled trials examined the cost effectiveness of adherence interventions. Despite that some studies showe favourable ICERs, the overall quality of studies was modest and the economic perspectives applied were frequently narrow. To demonstrate that adherence interventions can be cost effective, we recommend that proven-effective adherence programmes are subjected to comprehensive economic evaluations.
Literature
1.
Sabaté E. Adherence to long-term therapies: evidence for action, vol. 7. Geneva: World Health Organization; 2003. p. 48–9.
2.
DiMatteo MR, Giordani PJ, Lepper HS, et al. Patient adherence and medical treatment outcomes. A meta-analysis. Med Care. 2002;40(9):794–811.PubMedCrossRef
3.
Knapp M, King D, Pugner K, et al. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiatry. 2004;184(6):509–16.PubMedCrossRef
4.
Colom F, Vieta E, Tacchi M, et al. Identifying and improving non-adherence in bipolar disorders. Bipolar Disord. 2005;7(s5):24–31.PubMedCrossRef
5.
White TJ, Vanderplas A, Ory C, et al. Economic impact of patient adherence with antidepressant therapy within a managed care organization. Dis Manage Health Outcome. 2003;11(12):817–22.CrossRef
6.
Bender BG, Rand C. Medication non-adherence and asthma treatment cost. Curr Opin Allergy Clin Immunol. 2004;4(3):191.PubMedCrossRef
7.
Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521–30.PubMedCrossRef
8.
Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther. 2006;28(10):1712–25.PubMedCrossRef
9.
Scalera A, Bayoumi AM, Oh P, et al. Clinical and economic implications of non-adherence to HAART in HIV infection. Dis Manage Health Outcome. 2002;10(2):85–91.CrossRef
10.
Goldie SJ, Paltiel AD, Weinstein MC, et al. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med. 2003;115(8):632.PubMedCrossRef
11.
12.
Mahoney JJ, Ansell BJ, Fleming FWK, et al. The unhidden cost of noncompliance. J Manage Care Pharm. 2008;14:S1–29.
13.
Cutler DM, Everett W. Thinking outside the pillbox—medication adherence as a priority for health care reform. N Engl J Med. 2010;362(17):1553–5.PubMedCrossRef
14.
Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;(2):CD000011.
15.
McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions. JAMA. 2002;288(22):2868–79.PubMedCrossRef
16.
Roebuck MC, Liberman JN, Gemmill-Toyama M, et al. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff. 2011;30(1):91–9.CrossRef
17.
Elliott RA, Barber N, Horne R. Cost-effectiveness of adherence-enhancing interventions: a quality assessment of the evidence. Ann Pharmacother. 2005;39(3):508–15.PubMedCrossRef
18.
Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. USA: Oxford University Press; 2005.
19.
Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.PubMedCrossRef
20.
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–74.PubMedCrossRef
21.
Jönsson B. Ten arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Health Econ. 2009;10(4):357–9.PubMedCrossRef
22.
Krol M, Brouwer W, Sendi P. Productivity costs in health-state valuations: does explicit instruction matter? Pharmacoeconomics. 2006;24(4):401–14.PubMedCrossRef
23.
Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8(2):165–78.PubMedCrossRef
24.
Bolton MB, Tilley BC, Kuder J, et al. The cost and effectiveness of an education program for adults who have asthma. J Gen Intern Med. 1991;6(5):401–7.PubMedCrossRef
25.
Bosmans JE, Brook OH, van Hout HPJ, et al. Cost effectiveness of a pharmacy-based coaching programme to improve adherence to antidepressants. Pharmacoeconomics. 2007;25(1):25–37.PubMedCrossRef
26.
Brunenberg DEM, Wetzels GEC, Nelemans PJ, et al. Cost effectiveness of an adherence-improving programme in hypertensive patients. Pharmacoeconomics. 2007;25(3):239–51.PubMedCrossRef
27.
Elliott RA, Barber N, Clifford S, et al. The cost effectiveness of a telephone-based pharmacy advisory service to improve adherence to newly prescribed medicines. Pharm World Sci. 2008;30(1):17–23.PubMedCrossRef
28.
Freedberg KA, Hirschhorn LR, Schackman BR, et al. Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients. J Acquir Immune Defic Syndr. 2006;43:S113–8.PubMedCrossRef
29.
Healey A, Knapp M, Astin J, et al. Cost-effectiveness evaluation of compliance therapy for people with psychosis. Br J Psychiatry. 1998;172(5):420–4.PubMedCrossRef
30.
Hederos CA, Janson S, Hedlin G. Group discussions with parents have long-term positive effects on the management of asthma with good cost–benefit. Acta Paediatr. 2005;94(5):602–8.PubMedCrossRef
31.
Keeler EB, Robalino DA, Frank JC, et al. Cost-effectiveness of outpatient geriatric assessment with an intervention to increase adherence. Med Care. 1999;37(12):1199–206.PubMedCrossRef
32.
Khdour MR, Agus AM, Kidney JC, et al. Cost–utility analysis of a pharmacy-led self-management programme for patients with COPD. Int J Clin Pharmacol. 2011;33(4):665–73.CrossRef
33.
Murray D, Stroupe KT, Wu J, et al. Pharmacist intervention to improve medication adherence in heart failure. Ann Intern Med. 2007;146:714–25.PubMedCrossRef
34.
Schroeder K, Fahey T, Hollinghurst S, et al. Nurse-led adherence support in hypertension: a randomized controlled trial. Fam Pract. 2005;22(2):144–51.PubMedCrossRef
35.
von Knorring L, Åkerblad AC, Bengtsson F, et al. Cost of depression: effect of adherence and treatment response. Eur Psychiat. 2006;21(6):349–54.CrossRef
36.
Von Korff M, Katon W, Bush T, et al. Treatment costs, cost offset, and cost-effectiveness of collaborative management of depression. Psychosom Med. 1998;60(2):143–9.
37.
Windsor RA, Bailey WC, Richards JM Jr, et al. Evaluation of the efficacy and cost effectiveness of health education methods to increase medication adherence among adults with asthma. Am J Public Health. 1990;80(12):1519–21.PubMedCrossRef
38.
de Bruin M, Viechtbauer W, Hospers HJ, et al. Standard care quality determines treatment outcomes in control groups of HAART-adherence intervention studies: implications for the interpretation and comparison of intervention effects. Health Psychol. 2009;28(6):668.PubMedCrossRef
39.
de Bruin M, Viechtbauer W, Schaalma HP, et al. Standard care impact on effects of highly active antiretroviral therapy adherence interventions: a meta-analysis of randomized controlled trials. Arch Intern Med. 2010;170(3):240.PubMedCrossRef
40.
Gafni A, Birch S. Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. Soc Sci Med. 2006;62(9):2091–100.PubMedCrossRef
41.
Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ. 1995;3(2):95–104.CrossRef
42.
Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10(8):779–87.PubMedCrossRef
43.
Briggs A. Economic evaluation and clinical trials: size matters. The need for greater power in cost analyses poses an ethical dilemma. BMJ. 2000;321(7273):1362–3.PubMedCrossRef
44.
Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med. 2000;19(23):3219–36.PubMedCrossRef
45.
Boutron I, Estellat C, Guittet L, et al. Methods of blinding in reports of randomized controlled trials assessing pharmacologic treatments: a systematic review. PLoS Med. 2006;3(10):e425.PubMedCrossRef
46.
Albrecht L, Archibald M, Arseneau D, Scott SD. Development of a checklist to assess the quality of reporting of knowledge translation interventions using the Workgroup for Intervention Development and Evaluation Research (WIDER) recommendations. Implement Sci. 2013;8:52.PubMedCrossRef
47.
Freedland KE, Mohr DC, Davidson KW, et al. Usual and unusual care: existing practice control groups in randomized controlled trials of behavioral interventions. Psychosom Med. 2011;73(4):323–35.PubMedCrossRef
Metadata
Title
Cost Effectiveness of Medication Adherence-Enhancing Interventions: A Systematic Review of Trial-Based Economic Evaluations
Authors
Edwin J. M. Oberjé
Reina J. A. de Kinderen
Silvia M. A. A. Evers
Cees M. J. van Woerkum
Marijn de Bruin
Publication date
01-12-2013
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 12/2013
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-013-0108-8

Other articles of this Issue 12/2013

PharmacoEconomics 12/2013 Go to the issue

Acknowledgement to Referees

Acknowledgments

Original Research Article

A Closer Look at Decision and Analyst Error by Including Nonlinearities in Discrete Choice Models: Implications on Willingness-to-Pay Estimates Derived from Discrete Choice Data in Healthcare

Review Article

Vemurafenib for the Treatment of Locally Advanced or Metastatic BRAF V600 Mutation-Positive Malignant Melanoma: A NICE Single Technology Appraisal

Commentary

Search MEDLINE for Economic Evaluations: Tips to Translate an OVID Strategy into a PubMed One

Practical Application

How to Include Informal Care in Economic Evaluations

Current Opinion

Assessing the Cost Effectiveness of Pre-Exposure Prophylaxis for HIV Prevention in the US